8 results on '"Michelle Romijn"'
Search Results
2. Identification of common and distinct origins of human serum and breastmilk IgA1 by mass spectrometry-based clonal profiling
- Author
-
Kelly A, Dingess, Max, Hoek, Danique M H, van Rijswijk, Sem, Tamara, Maurits A, den Boer, Tim, Veth, Mirjam J A, Damen, Arjan, Barendregt, Michelle, Romijn, Hannah G, Juncker, Britt J, van Keulen, Gestur, Vidarsson, Johannes B, van Goudoever, Albert, Bondt, and Albert J R, Heck
- Abstract
The most abundant immunoglobulin present in the human body is IgA. It has the highest concentrations at the mucosal lining and in biofluids such as milk and is the second most abundant class of antibodies in serum. We assessed the structural diversity and clonal repertoire of IgA1-containing molecular assemblies longitudinally in human serum and milk from three donors using a mass spectrometry-based approach. IgA-containing molecules purified from serum or milk were assessed by the release and subsequent analysis of their Fab fragments. Our data revealed that serum IgA1 consists of two distinct structural populations, namely monomeric IgA1 (∼80%) and dimeric joining (J-) chain coupled IgA1 (∼20%). Also, we confirmed that IgA1 in milk is present solely as secretory (S)IgA, consisting of two (∼50%), three (∼33%) or four (∼17%) IgA1 molecules assembled with a J-chain and secretory component (SC). Interestingly, the serum and milk IgA1-Fab repertoires were distinct between monomeric, and J-chain coupled dimeric IgA1. The serum dimeric J-chain coupled IgA1 repertoire contained several abundant clones also observed in the milk IgA1 repertoire. The latter repertoire had little to no overlap with the serum monomeric IgA1 repertoire. This suggests that human IgA1s have (at least) two distinct origins; one of these produces dimeric J-chain coupled IgA1 molecules, shared in human serum and milk, and another produces monomeric IgA1 ending up exclusively in serum.
- Published
- 2022
3. Humans have distinct repertoires of IgA1
- Author
-
Kelly A. Dingess, Max Hoek, Danique M.H. van Rijswijk, Sem Tamara, Maurits A. den Boer, Mirjam J.A. Damen, Arjan Barendregt, Michelle Romijn, Hannah G. Juncker, Britt J. van Keulen, Gestur Vidarsson, Johannes B. van Goudoever, Albert Bondt, and Albert J.R. Heck
- Subjects
fluids and secretions ,stomatognathic system ,chemical and pharmacologic phenomena - Abstract
The most abundant immunoglobulin present in the human body is IgA1. It has the highest concentrations at the mucosal lining and in biofluids such as milk and is the second most abundant class of antibodies in serum. We assessed the structural diversity and clonal repertoire of IgA1-containing molecular assemblies longitudinally in human serum and milk from three donors using a mass spectrometry-based approach. IgA-containing molecules purified from serum or milk were assessed by the release and subsequent analysis of their Fab fragments. Our data revealed that serum IgA1 consists of two distinct structural populations, namely monomeric IgA1 (∼ 80%) and dimeric joining (J-) chain coupled IgA1 (∼ 20%). Also, we confirmed that IgA1 in milk is present solely as secretory (S)IgA, consisting of two (∼ 50%), three (∼ 33%) or four (∼ 17%) IgA1 molecules assembled with a J-chain and secretory component (SC). Interestingly, the serum and milk IgA1-Fab repertoires were distinct between monomeric, and J-chain coupled dimeric IgA1. The serum dimeric J-chain coupled IgA1 repertoire contained several abundant clones also observed in the milk IgA1 repertoire. The latter repertoire had little to no overlap with the serum monomeric IgA1 repertoire. This suggests that human IgA1s have (at least) two distinct origins; one of these produces dimeric J-chain coupled IgA1 molecules, shared in human serum and milk, and another produces monomeric IgA1 ending up exclusively in serum.
- Published
- 2022
4. Bronchopulmonary dysplasia is not related to neurofilament light for neuroaxonal damage in preterm infants
- Author
-
Michelle, Romijn, Emma M, Baas, Birgit I, Lissenberg-Witte, Wes, Onland, Marsh, Königs, Jaap, Oosterlaan, Hans, Heijst, Joost, Rotteveel, Anton H, van Kaam, Charlotte E, Teunissen, and Martijn J J, Finken
- Abstract
Neurofilament light (NfL) has been identified as a biomarker for neuroaxonal damage in preterm infants, but its relation with bronchopulmonary dysplasia (BPD) has not been established. We hypothesized that BPD is associated with increased NfL levels at an early stage, indicative of early neuroaxonal damage.We included preterm infants born30 weeks of gestation for assessment of NfL levels from cord blood and blood obtained at postnatal days 3, 7, 14, and 28. We used linear regression analysis to compare NfL levels between infants with moderate/severe BPD and infants with no/mild BPD, and linear mixed model analysis to compare the effect of time on NfL levels between groups.Sixty-seven infants with a gestational age (GA) of 27 ± 1.3 weeks were included for analysis, of whom 19 (28%) developed moderate/severe BPD. Although NfL levels were higher at every time point in infants with BPD, statistical significance was lost after adjustment for GA, small for gestational age (SGA) and intraventricular hemorrhage (IVH). Groups did not differ in NfL change over time.The positive association between BPD and NfL in the first weeks of life could be explained by GA, SGA and IVH rather than by development of BPD.Neurofilament light chain (NfL) is a known biomarker for neuroaxonal damage. Biomarkers for brain damage during the first weeks of life in preterm infants developing BPD are lacking. NfL levels obtained during the first weeks of life did not differ between infants with and without BPD in analyses adjusted for GA, SGA, and IVH.
- Published
- 2022
5. Sex-specific differences in HPA axis activity in VLBW preterm newborns
- Author
-
Britt J. van Keulen, Marita de Waard, Michaela F. Hartmann, Johannes B. van Goudoever, Bibian van der Voorn, Michelle Romijn, Stefan A. Wudy, Martijn J J Finken, Joost Rotteveel, General Paediatrics, Neonatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ARD - Amsterdam Reproduction and Development, VUmc - School of Medical Sciences, Youth and Lifestyle, Network Institute, Pediatrics, Pediatric surgery, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Reproduction & Development (AR&D), Amsterdam Gastroenterology Endocrinology Metabolism, and ACS - Diabetes & metabolism
- Subjects
Endocrinology, Diabetes and Metabolism ,Physiology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Excretion ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,SDG 3 - Good Health and Well-being ,030225 pediatrics ,Internal Medicine ,medicine ,Prospective cohort study ,metabolites ,lcsh:RC648-665 ,business.industry ,Research ,steroid ,medicine.disease ,Sexual dimorphism ,Postnatal age ,Low birth weight ,Bronchopulmonary dysplasia ,sexual dimorphism ,glucocorticoid ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Glucocorticoid ,medicine.drug - Abstract
Objective Sex-specific differences in hypothalamic–pituitary–adrenal axis activity might explain why male preterm infants are at higher risk of neonatal mortality and morbidity than their female counterparts. We examined whether male and female preterm infants differed in cortisol production and metabolism at 10 days post-partum. Design and methods This prospective study included 36 preterm born infants (18 boys) with a very low birth weight (VLBW) ( Results No differences between sexes were found for cortisol excretion rate, corticosteroid excretion rate or 11B-HSD activity. Interaction was observed between: sex and SNAPPE II score on 11B-HSD activity (P = 0.04) and sex and BPD on cortisol excretion rate (P = 0.04). Conclusion This study did not provide evidence for sex-specific differences in adrenocortical function in preterm VLBW infants on a group level. However, in an interaction model, sex differences became manifest under stressful circumstances. These patterns might provide clues for the male disadvantage in neonatal mortality and morbidity following preterm birth. However, due to the small sample size, the data should be seen as hypothesis generating.
- Published
- 2020
6. Breastmilk; a source of SARS-CoV-2 specific IgA antibodies
- Author
-
Britt J. van Keulen, Michelle Romijn, Albert Bondt, Kelly A. Dingess, Eva Kontopodi, Karlijn van der Straten, Maurits A. den Boer, Berend J. Bosch, Philip J.M. Brouwer, Christianne J.M. de Groot, Max Hoek, Wentao Li, Dasja Pajkrt, Rogier W. Sanders, Anne Schoonderwoerd, Sem Tamara, Rian A.H. Timmermans, Gestur Vidarsson, Koert J. Stittelaar, Theo T. Rispens, Kasper A. Hettinga, Marit J. van Gils, Albert J.R. Heck, and Johannes B. van Goudoever
- Subjects
viruses ,skin and connective tissue diseases - Abstract
BackgroundSince the outbreak of COVID-19, many put their hopes in the rapid development of effective immunizations. For now patient isolation, physical distancing and good hygiene are the sole measures for prevention. Processed breast milk with antibodies against SaRS-CoV-2 may serve as additional protection. We aimed to determine the presence and neutralization capacity of antibodies against SaRS-CoV-2 in breastmilk of mothers who have recovered from COVID-19.MethodsThis prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Serum and breastmilk was collected. To assess the presence of antibodies in breastmilk and serum, we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein, SARS-CoV-2 receptor binding domain (RBD) and with the SARS-CoV-2 nucleocapsid (N) protein for IgG and bridging ELISA with the SARS-CoV-2 RBD and N protein for total Ig. To assess the effect of pasteurization breastmilk was exposed to Holder Pasteurization and High Pressure Pasteurization.ResultsBreastmilk contained antibodies against SARS-CoV-2 using any of the assays in 24 out of 29 (83%) proven cases, in six out of nine (67%) suspected cases and in none of the 13 controls.In vitroneutralization of SARS-CoV-2 clinical isolate virus strain was successful in a subset of serum (13%) and milk samples (26%). Although after pasteurization of the milk SARS-CoV-2 antibodies were detected with both methods of pasteurization, virus neutralizing capacity of those antibodies was only retained with the HPP approach.ConclusionBreastmilk of mothers who recovered from COVID-19 contains significant amounts of IgA against SARS-CoV-2, both before and after pasteurization.Key PointsQuestionDoes breastmilk of mothers who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?FindingsWe provide multiple lines of evidence on the presence of a variety of antibodies against SARS-CoV-2, with no such antibodies present in the controls. These antibodies are capable of neutralizing a clinical isolate of SARS-CoV-2in vitro. We furthermore show that high pressure pasteurization hardly affects antibody levels and efficacy.MeaningBreastmilk, obtained from mothers who have recovered from COVID-19, may serve as a safe and widely applicable preventive strategy for vulnerable high risk populations
- Published
- 2020
7. No association between glucocorticoid receptor polymorphisms and long-term respiratory outcome after very preterm birth
- Author
-
Emma M, Baas, Michelle, Romijn, Sylvia M, van der Pal, Elianne J L E, Vrijlandt, Joost, Rotteveel, Martijn J J, Finken, and G J, van Steenbrugge
- Subjects
Polymorphism, Genetic ,Receptors, Glucocorticoid ,Pregnancy ,Infant, Newborn ,Humans ,Premature Birth ,Female ,Gestational Age - Published
- 2020
8. Breastmilk: A Source of SARS-CoV-2 Specific IgA Antibodies
- Author
-
Albert J. R. Heck, Eva Kontopodi, Kelly A Dingess, Koert J. Stittelaar, Gestur Vidarsson, Max Hoek, Sem Tamara, Anne Schoonderwoerd, Theo Rispens, Christianne J.M. de Groot, Berend J. Bosch, Roger W Sanders, Michelle Romijn, Marit J. van Gils, Maurits A. den Boer, R.A.H. Timmermans, Karlijn van der Straten, Kasper Hettinga, Dasja Pajkrt, Wentao Li, Albert Bondt, Philip J. M. Brouwer, Johannes B. van Goudoever, and Britt J. van Keulen
- Subjects
biology ,business.industry ,viruses ,Case-control study ,Outbreak ,Pasteurization ,Breast milk ,Virology ,Virus ,Neutralization ,law.invention ,medicine.anatomical_structure ,law ,Lactation ,biology.protein ,Medicine ,Antibody ,skin and connective tissue diseases ,business - Abstract
Background Since the outbreak of COVID-19, many put their hopes in the rapid development of effective immunizations. For now patient isolation, physical distancing and good hygiene are the sole measures for prevention. Processed breast milk with antibodies against SaRS-CoV-2 may serve as additional protection. We aimed to determine the presence and neutralization capacity of antibodies against SaRS-CoV-2 in breastmilk of mothers who have recovered from COVID-19. Methods This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Serum and breastmilk was collected. To assess the presence of antibodies in breastmilk and serum, we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein, SARS-CoV-2 receptor binding domain (RBD) and with the SARS-CoV-2 nucleocapsid (N) protein for IgG and bridging ELISA with the SARS-CoV-2 RBD and N protein for total Ig. To assess the effect of pasteurization breastmilk was exposed to Holder Pasteurization and High Pressure Pasteurization. Results Breastmilk contained antibodies against SARS-CoV-2 using any of the assays in 24 out of 29 (83%) proven cases, in six out of nine (67%) suspected cases and in none of the 13 controls. In vitro neutralization of SARS-CoV-2 clinical isolate virus strain was successful in a subset of serum (13%) and milk samples (26%). Although after pasteurization of the milk SARS-CoV-2 antibodies were detected with both methods of pasteurization, virus neutralizing capacity of those antibodies was only retained with the HPP approach. Conclusion Breastmilk of mothers who recovered from COVID-19 contains significant amounts of IgA against SARS-CoV-2, both before and after pasteurization. Key Points Question Does breastmilk of mothers who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? Findings We provide multiple lines of evidence on the presence of a variety of antibodies against SARS-CoV-2, with no such antibodies present in the controls. These antibodies are capable of neutralizing a clinical isolate of SARS-CoV-2 in vitro. We furthermore show that high pressure pasteurization hardly affects antibody levels and efficacy. Meaning Breastmilk, obtained from mothers who have recovered from COVID-19, may serve as a safe and widely applicable preventive strategy for vulnerable high risk populations
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.